Eli Lilly Phase 3 RELAY study meets PFS primary endpoint

 Eli Lilly announced that its Phase 3 RELAY study of Cyramza met its primary endpoint of progression-free survival, or PFS, demonstrating a statistically significant improvement in the time patients lived without their cancer growing or spreading after starting treatment. The Phase 3 global, randomized, double-blind trial is evaluating Cyramza in combination with erlotinib, compared to placebo in combination with erlotinib, as a first-line treatment in patients with metastatic non-small cell lung cancer, or NSCLC, whose tumors have activating EGFR mutations. The safety profile observed in the RELAY study was consistent with what has been previously observed for Cyramza in Phase 3 clinical trials and the established safety profile of erlotinib. The most common Grade 3 adverse events occurring at a higher rate on the Cyramza-plus-erlotinib arm compared to the placebo-plus-erlotinib arm were hypertension, dermatitis acneiform and diarrhea. Detailed efficacy and safety results will be submitted for presentation at a medical meeting.


https://thefly.com/landingPageNews.php?id=2877625